Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DGX NASDAQ:EXAS NASDAQ:MYGN NASDAQ:NTRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$195.53-0.3%$194.48$164.65▼$213.50$21.68B0.6957,314 shs339,199 shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/AMYGNMyriad Genetics$3.96-6.3%$4.45$3.53▼$8.59$374.49M1.811.59 million shs1.13 million shsNTRANatera$220.47+3.1%$201.85$131.81▼$256.36$31.59B1.571.32 million shs1.34 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics+1.25%+1.55%+0.86%-7.12%+14.89%EXASExact Sciences0.00%0.00%0.00%+1.48%+80.63%MYGNMyriad Genetics+7.38%+7.93%-12.81%-8.46%-2.54%NTRANatera+5.33%+5.03%+6.78%+2.84%+32.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDGXQuest Diagnostics$195.53-0.3%$194.48$164.65▼$213.50$21.68B0.6957,314 shs339,199 shsEXASExact Sciences$104.91$103.67$38.81▼$104.98$20.03B1.413.55 million shsN/AMYGNMyriad Genetics$3.96-6.3%$4.45$3.53▼$8.59$374.49M1.811.59 million shs1.13 million shsNTRANatera$220.47+3.1%$201.85$131.81▼$256.36$31.59B1.571.32 million shs1.34 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDGXQuest Diagnostics+1.25%+1.55%+0.86%-7.12%+14.89%EXASExact Sciences0.00%0.00%0.00%+1.48%+80.63%MYGNMyriad Genetics+7.38%+7.93%-12.81%-8.46%-2.54%NTRANatera+5.33%+5.03%+6.78%+2.84%+32.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDGXQuest Diagnostics 2.50Moderate Buy$216.5810.77% UpsideEXASExact Sciences 1.95Reduce$92.13-12.19% DownsideMYGNMyriad Genetics 2.00Hold$6.5064.35% UpsideNTRANatera 2.79Moderate Buy$256.6016.39% UpsideCurrent Analyst Ratings BreakdownLatest MYGN, DGX, EXAS, and NTRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026DGXQuest Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B+) ➝ Buy (B)5/18/2026MYGNMyriad Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026NTRANatera Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$249.005/11/2026NTRANatera BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$260.00 ➝ $250.005/8/2026NTRANatera Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$265.005/8/2026NTRANatera EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$270.005/8/2026NTRANatera JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $265.005/8/2026NTRANatera Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$215.00 ➝ $220.005/6/2026MYGNMyriad Genetics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$7.00 ➝ $6.005/6/2026MYGNMyriad Genetics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$6.00 ➝ $5.505/4/2026DGXQuest Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B) ➝ Buy (B+)(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDGXQuest Diagnostics$11.04B1.96$15.30 per share12.78$69.25 per share2.82EXASExact Sciences$3.25B6.17$1.27 per share82.83$12.58 per share8.34MYGNMyriad Genetics$824.50M0.45$3.80 per share1.04$3.57 per share1.11NTRANatera$2.31B13.69N/AN/A$12.39 per share17.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDGXQuest Diagnostics$992M$9.0521.6416.912.319.07%15.60%7.06%7/28/2026 (Estimated)EXASExact Sciences-$207.95M-$1.10N/A209.822.02-6.40%0.53%0.22%N/AMYGNMyriad Genetics-$365.90M-$4.30N/AN/AN/A-48.24%-8.51%-4.48%8/4/2026 (Estimated)NTRANatera-$208.16M-$1.63N/A881.90N/A-9.05%-14.74%-10.27%8/6/2026 (Estimated)Latest MYGN, DGX, EXAS, and NTRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026MYGNMyriad Genetics-$0.06-$0.09-$0.03-$0.36$202.42 million$200.40 million4/21/2026Q1 2026DGXQuest Diagnostics$2.37$2.50+$0.13$2.24$2.83 billion$2.90 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDGXQuest Diagnostics$3.441.76%+7.34%38.01%14 YearsEXASExact SciencesN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ALatest MYGN, DGX, EXAS, and NTRA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/19/2026DGXQuest Diagnosticsquarterly$0.861.81%7/8/20267/8/20267/22/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDGXQuest Diagnostics0.671.181.08EXASExact Sciences0.972.432.17MYGNMyriad Genetics0.362.402.19NTRANateraN/A2.962.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDGXQuest Diagnostics88.06%EXASExact Sciences88.82%MYGNMyriad Genetics99.02%NTRANatera99.90%Insider OwnershipCompanyInsider OwnershipDGXQuest Diagnostics0.88%EXASExact Sciences1.20%MYGNMyriad Genetics1.90%NTRANatera5.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDGXQuest Diagnostics57,000110.70 million109.72 millionOptionableEXASExact Sciences7,200190.89 million188.60 millionOptionableMYGNMyriad Genetics2,70094.45 million92.65 millionOptionableNTRANatera6,140143.21 million135.15 millionOptionableMYGN, DGX, EXAS, and NTRA HeadlinesRecent News About These CompaniesWhy Natera Is My Favorite Stock Idea for the Rest of 2026May 29 at 10:26 AM | 247wallst.comNatera (NASDAQ:NTRA) Insider John Fesko Sells 1,438 SharesMay 29 at 8:15 AM | insidertrades.comSBI Okasan Asset Management Co.Ltd. Purchases Shares of 8,200 Natera, Inc. $NTRAMay 29 at 7:03 AM | marketbeat.comNatera Announces Collaboration with Diakonos Oncology for Signateraâ„¢ in Refractory MelanomaMay 29 at 7:00 AM | gurufocus.comJTC Employer Solutions Trustee Ltd Invests $5 Million in Natera, Inc. $NTRAMay 29 at 6:45 AM | marketbeat.comNatera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory MelanomaMay 29 at 6:00 AM | businesswire.comAllstate Corp Acquires 5,084 Shares of Natera, Inc. $NTRAMay 29 at 3:05 AM | marketbeat.comJohn Fesko Sells 1,438 Shares of Natera (NASDAQ:NTRA) StockMay 28 at 11:17 PM | marketbeat.comNatera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,652 SharesMay 28 at 11:17 PM | marketbeat.comNatera price target raised to $250 from $200 at CanaccordMay 28 at 12:45 PM | msn.comNatera to Launch Enhanced Panorama NIPT for Low Fetal FractionsMay 28 at 12:06 PM | zacks.com17,343 Shares in Natera, Inc. $NTRA Purchased by Leeward Financial Partners LLCMay 28 at 6:06 AM | marketbeat.comNatera: A Growing Biotech, After Recent FDA Approval And Q1 Revenue ResultsMay 27 at 8:01 AM | seekingalpha.comBellwether Advisors LLC Acquires Shares of 9,496 Natera, Inc. $NTRAMay 27 at 3:29 AM | marketbeat.comNatera Expands Austin Operations With New Sequencing FacilityMay 26 at 12:01 PM | zacks.comNatera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing TechnologyMay 26 at 7:50 AM | finance.yahoo.com14,887 Shares in Natera, Inc. $NTRA Purchased by Nia Impact Advisors LLCMay 25, 2026 | marketbeat.comHighTower Advisors LLC Buys 66,896 Shares of Natera, Inc. $NTRAMay 24, 2026 | marketbeat.comHow The Natera (NTRA) Investment Story Is Shifting With New Guidance And Analyst RevisionsMay 24, 2026 | finance.yahoo.comPinnbrook Capital Management LP Increases Stock Position in Natera, Inc. $NTRAMay 22, 2026 | marketbeat.comNatera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in OncologyMay 21, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026IREN Is Flipping the Switch from Bitcoin to AIBy Jeffrey Neal Johnson | May 28, 2026AI’s Biggest Bottleneck Could Make These 2 Stocks SoarBy Jeffrey Neal Johnson | May 28, 2026MYGN, DGX, EXAS, and NTRA Company DescriptionsQuest Diagnostics NYSE:DGX$195.52 -0.68 (-0.34%) As of 03:27 PM Eastern This is a fair market value price provided by Massive. Learn more.Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Exact Sciences NASDAQ:EXASExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Myriad Genetics NASDAQ:MYGN$3.96 -0.27 (-6.28%) As of 03:27 PM Eastern This is a fair market value price provided by Massive. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Natera NASDAQ:NTRA$220.47 +6.53 (+3.05%) As of 03:27 PM Eastern This is a fair market value price provided by Massive. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
